Literature DB >> 35274394

Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya.

Matthew J Akiyama1, Lindsey R Riback1, Mercy Nyakowa2, Helgar Musyoki2, John A Lizcano3, Abbe Muller3, Chenshu Zhang1, Josephine G Walker4, Jack Stone4, Peter Vickerman4, Peter Cherutich2, Ann E Kurth3.   

Abstract

Entities:  

Keywords:  Africa; DAA; HCV; LMIC; PWID

Mesh：

Substances：

Year:  2022        PMID： 35274394      PMCID： PMC9276623          DOI： 10.1111/jvh.13662

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN： 1352-0504            Impact factor:   3.517


× No keyword cloud information.
  8 in total

Review 1.  Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.

Authors: 
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-12-16

Review 2.  Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030.

Authors:  Mark W Sonderup; Mary Afihene; Reidwaan Ally; Betty Apica; Yaw Awuku; Lina Cunha; Geoffrey Dusheiko; Neliswa Gogela; Marie-Jeanne Lohouès-Kouacou; Phillip Lam; Olufunmilayo Lesi; Papa Saliou Mbaye; Emmanuel Musabeyezu; Betty Musau; Olesegun Ojo; John Rwegasha; Barbara Scholz; Abate B Shewaye; Christian Tzeuton; Chris Kassianides; C Wendy Spearman
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-12

3.  Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.

Authors:  Neil Gupta; Aimable Mbituyumuremyi; Jules Kabahizi; Fabien Ntaganda; Claude Mambo Muvunyi; Fabienne Shumbusho; Emmanuel Musabeyezu; Constance Mukabatsinda; Cyprien Ntirenganya; Jennifer Ilo Van Nuil; Fredrick Kateera; Gregory Camus; Makuza Jean Damascene; Sabin Nsanzimana; Joia Mukherjee; Philip M Grant
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-12-11

4.  Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.

Authors:  Alyona Mazhnaya; Anna Meteliuk; Tetiana Barnard; Alexei Zelenev; Sergii Filippovych; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2017-08-12

5.  Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.

Authors:  Mustafizur Rahman; Naveed Zafar Janjua; Tanveer Khan Ibne Shafiq; Ezazul Islam Chowdhury; Md Safiullah Sarker; Sharful Islam Khan; Masud Reza; Mohammad Omar Faruque; Ahmedul Kabir; Aslam H Anis; Tasnim Azim
Journal:  Int J Drug Policy       Date:  2019-09-19

6.  Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.

Authors:  Matthew J Akiyama; Charles M Cleland; John A Lizcano; Peter Cherutich; Ann E Kurth
Journal:  Lancet Infect Dis       Date:  2019-09-17       Impact factor: 25.071

Review 7.  Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.

Authors:  Louisa Degenhardt; Amy Peacock; Samantha Colledge; Janni Leung; Jason Grebely; Peter Vickerman; Jack Stone; Evan B Cunningham; Adam Trickey; Kostyantyn Dumchev; Michael Lynskey; Paul Griffiths; Richard P Mattick; Matthew Hickman; Sarah Larney
Journal:  Lancet Glob Health       Date:  2017-10-23       Impact factor: 26.763

8.  Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus#x02010;co#x02010;infected patients in Myanmar.

Authors:  Yin Min Thaung; Charles S Chasela; Kara W Chew; Thomas Minior; Aye A Lwin; Yi Y Sein; Ndeye Drame; Fadzai Marange; Charles van der Horst; Hnin T Thwin; Morgan J Freiman; Malini M Gandhi; Murdo Bijl; Constance Wose Kinge; Sydney Rosen; Si Thura; Sofiane Mohamed; Thembisile Xulu; Aung Y Naing; Matthiue Barralon; Clint Cavenaugh; Khin P Kyi; Ian Sanne
Journal:  J Viral Hepat       Date:  2020-09-16       Impact factor: 3.728
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.